Fundamentals make it easy to get excited about senior living, expert says
By
Kimberly Bonvissuto
Mar 18, 2024
With solid demand, increasing occupancy and reduced supply, the underlying fundamentals driving top-line revenue growth in senior living are good, making it difficult not to get excited about the sector...
New report contains surprises about best places to retire
By
Kimberly Bonvissuto
Aug 01, 2022
Vermont is the best state — and Hartford, CT, is the best city — overall in the nation for senior living, according to a recent report examining quality-of-life factors for older adults.
Labor, enforcement trends creating operational, financial challenges for senior living
By
Kimberly Bonvissuto
Jul 22, 2022
Labor, behavioral health and the regulatory agenda are among the key 2022 trends that continue causing operational and financial challenges for senior living and other long-term care providers.
Court strikes down pandemic liability shield law for assisted living providers
By
Kimberly Bonvissuto
Oct 02, 2023
A state COVID-19 immunity shield law for assisted living and other providers has been ruled unconstitutional, which could have major implications for long-term care and other healthcare providers in Arizona.
Education, leadership keys to combating vaccine hesitancy in senior living, experts say
By
Kimberly Bonvissuto
Jan 10, 2024
Increasing COVID-19, influenza and respiratory vaccination rates in older adults is going to require a village to battle vaccine reluctance in the form of misinformation, hesitancy and fatigue, according...
National senior living benchmarks can help providers use statistics to make decisions
By
Kimberly Bonvissuto
May 09, 2023
NEW ORLEANS—Senior living providers who have tools to measure, track and analyze relevant sales performance metrics are in an ideal position to implement best practices and optimize their sales teams...
Alzheimer’s experts throw support behind experimental drug despite adverse events, deaths
By
Kimberly Bonvissuto
Dec 01, 2022
Alzheimer’s disease experts are throwing their support behind the drug lecanemab, despite reports of two deaths tied to the experimental monoclonal antibody medication.